PMID- 15680279
OWN - NLM
STAT- MEDLINE
DCOM- 20050714
LR  - 20181201
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 508
IP  - 1-3
DP  - 2005 Jan 31
TI  - Therapeutic potential of thiazolidinediones in activation of peroxisome 
      proliferator-activated receptor gamma for monocyte recruitment and endothelial 
      regeneration.
PG  - 255-65
AB  - Thiazolidinediones, a new class of antidiabetic drugs that increase insulin 
      sensitivity, have been shown to be ligands for peroxisome proliferator-activated 
      receptor gamma (PPARgamma). Recent studies demonstrating that PPARgamma occurs in 
      macrophages have focused attention on its role in macrophage functions. In this 
      study, we investigated the effect of thiazolidinediones on monocyte proliferation 
      and migration in vitro and the mechanisms involved. In addition, we examined the 
      therapeutic potentials of thiazolidinediones for injured atherosclerotic lesions. 
      Troglitazone and pioglitazone, the two thiazolidinediones, as well as 
      15-deoxy-delta12,14-prostaglandin J2 inhibited in a dose-dependent manner the 
      serum-induced proliferation of THP-1 (human monocytic leukemia cells) and of U937 
      (human monoblastic leukemia cells), which permanently express PPARgamma. These 
      ligands for PPARgamma also significantly inhibited migration of THP-1 induced by 
      monocyte chemoattractant protein-1 (MCP-1). Troglitazone and 
      15-deoxy-delta12,14-prostaglandin J2 significantly suppressed the mRNA expression 
      of the MCP family-specific receptor CCR2 (chemokine CCR2 receptor) in THP-1 at 
      the transcriptional level. Furthermore, troglitazone significantly inhibited 
      MCP-1 binding to THP-1. Oral administration of troglitazone to Watanabe heritable 
      hyperlipidemic (WHHL) rabbits after balloon injury suppressed acute recruitment 
      of monocytes/macrophages and accelerated re-endothelialization. These results 
      suggest that thiazolidinediones have therapeutic potential for the treatment of 
      diabetic vascular complications.
FAU - Tanaka, Tokuji
AU  - Tanaka T
AD  - Department of Medicine and Clinical Science, Kyoto University Graduate School of 
      Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Fukunaga, Yasutomo
AU  - Fukunaga Y
FAU - Itoh, Hiroshi
AU  - Itoh H
FAU - Doi, Kentaro
AU  - Doi K
FAU - Yamashita, Jun
AU  - Yamashita J
FAU - Chun, Tae-Hwa
AU  - Chun TH
FAU - Inoue, Mayumi
AU  - Inoue M
FAU - Masatsugu, Ken
AU  - Masatsugu K
FAU - Saito, Takatoshi
AU  - Saito T
FAU - Sawada, Naoki
AU  - Sawada N
FAU - Sakaguchi, Satsuki
AU  - Sakaguchi S
FAU - Arai, Hiroshi
AU  - Arai H
FAU - Nakao, Kazuwa
AU  - Nakao K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20041230
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (15-deoxy-delta(12,14)-prostaglandin J2)
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chromans)
RN  - 0 (PPAR gamma)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, CCR2)
RN  - 0 (Receptors, Chemokine)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 1UA8E65KDZ (Alitretinoin)
RN  - 5688UTC01R (Tretinoin)
RN  - I66ZZ0ZN0E (Troglitazone)
RN  - RXY07S6CZ2 (Prostaglandin D2)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Alitretinoin
MH  - Angioplasty, Balloon/adverse effects
MH  - Animals
MH  - Aorta/drug effects/injuries/pathology
MH  - Arteriosclerosis/prevention & control
MH  - Binding, Competitive/drug effects
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Chemokine CCL2/metabolism/pharmacology
MH  - Chromans/pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/*drug effects/injuries/physiopathology
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Macrophages/drug effects/metabolism/pathology
MH  - Male
MH  - Monocytes/*drug effects/metabolism/pathology
MH  - PPAR gamma/*genetics
MH  - Pioglitazone
MH  - Prostaglandin D2/*analogs & derivatives/pharmacology
MH  - RNA, Messenger/genetics/metabolism
MH  - Rabbits
MH  - Receptors, CCR2
MH  - Receptors, Chemokine/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Thiazolidinediones/*pharmacology/therapeutic use
MH  - Time Factors
MH  - Tretinoin/pharmacology
MH  - Troglitazone
MH  - Vascular Endothelial Growth Factor A/genetics
MH  - Wound Healing/drug effects
EDAT- 2005/02/01 09:00
MHDA- 2005/07/15 09:00
CRDT- 2005/02/01 09:00
PHST- 2004/07/08 00:00 [received]
PHST- 2004/10/18 00:00 [revised]
PHST- 2004/10/28 00:00 [accepted]
PHST- 2005/02/01 09:00 [pubmed]
PHST- 2005/07/15 09:00 [medline]
PHST- 2005/02/01 09:00 [entrez]
AID - S0014-2999(04)01240-3 [pii]
AID - 10.1016/j.ejphar.2004.10.056 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2005 Jan 31;508(1-3):255-65. doi: 10.1016/j.ejphar.2004.10.056. 
      Epub 2004 Dec 30.